Plant Biotechnology – 22nd Century Group, Inc.’s (NASDAQ: XXII) ($XXII) interview with James Mish, CEO


22nd Century Group, Inc.’s  (NASDAQ: XXII) ($XXII) CEO, James Mish, talks with New to The Street’s TV Host Jane King. From the Nasdaq MarketSite studio, James explains the Company’s business in plant-based biotechnologies that creates health and wellness products, particularly reducing nicotine tobacco and advancing cannabinoid ingredients. The Company’s tobacco product, the VLN® cigarettes, is the first and only 95% reduced nicotine tobacco product with an FDA Modified Risk Tobacco Product (MRTP) authorization. James explains how cigarettes help curb smoking habits to get people to stop smoking completely. Smoking less reduces the long-term harmful effects associated with tobacco. The FDA wants to ban menthol cigarettes and implement industry mandates to produce low-level nicotine tobacco products. James tells viewers the Company’s cigarettes are the first of its kind in the marketplace, and the nicotine levels would be consistent with the FDA’s forthcoming mandates. Clinical studies have shown that the VLN product can reduce smoking by about 60%, and the cigarette package states, “Helps You Stop Smoking.” The tobacco industry is over $800B annually, so the Company plans to expand into other global markets and is currently doing operational pilot projects in Japan, Switzerland, and S. Korea. The on-screen QR code is available during the show; download or visit 22nd Century Group, Inc. –

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:

Follow New to the Street on Facebook:

Follow New to the Street on Instagram:

Follow New to the Street on Rumble:

About New to the Street:

Subscribe to our Mailing List: